24 C
New York
Saturday, July 5, 2025

Tag: data collection

Digital Twin Market Size to hit USD 140.93 billion by 2031, Experiences Growth Due to Increasing Adoption of IoT Devices, Large-Scale Digital Transformation |...

NEW YORK, July 4, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global digital twin market is observing significant...

Digital Twin Market Size to hit USD 140.93 billion by 2031, Experiences Growth Due to Increasing Adoption of IoT Devices, Large-Scale Digital Transformation |...

NEW YORK, July 4, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global digital twin market is observing significant...

Services PMI® at 50.8%; June 2025 Services ISM® Report On Business®

Business Activity Index at 54.2%; New Orders Index at 51.3%; Employment Index at 47.2%; Supplier Deliveries Index at 50.3% TEMPE, Ariz., July 3, 2025 /PRNewswire/...

Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center

Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) in Tel Aviv, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable patient enrollment at TASMC, a leading clinical site in Israel, prior to commencing this first-in-human trial at the site.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsData collection